$PHVS

Schikan Johannes Gerardus Christiaan Petrus sold $84K of PHVS

Schikan Johannes Gerardus Christiaan Petrus sold 2,400 shares of Pharvaris N.V. (PHVS) at $35.10 on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schikan Johannes Gerardus Christiaan Petrus
Published Jun 29, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

A director’s pre-arranged open-market sale is typically low-signal for fundamentals; traders may only adjust short-term sentiment or monitor for future non-10b5-1 activity.

02

Market read

Disclosed insider selling amount ($84.25K) is modest and explicitly pre-arranged, implying limited trading edge.

03

What to watch

Insider sales under 10b5-1 can be scheduled regardless of company outlook; the filing doesn’t include any new operational or clinical catalyst.

Relevance 2/10Novelty 3/10Timing: filed 2026-06-29 (after-hours) for a same-day 10b5-1 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

SEC Form 4 shows director Schikan sold 2,400 PHVS shares on 2026-06-29 under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The sale may be purely liquidity/tax-driven under the 10b5-1 plan, so it shouldn’t be treated as a bearish fundamental signal.

Key entities

  • Pharvaris N.V.

    Company subject of the Form 4 insider transaction disclosure.

  • Schikan Johannes Gerardus Christiaan Petrus

    Director who sold 2,400 shares on 2026-06-29 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.